Cannabinoid 2 receptor induction by IL-12 and its potential as a therapeutic target for the treatment of anaplastic thyroid carcinoma
- 21 December 2007
- journal article
- Published by Springer Science and Business Media LLC in Cancer Gene Therapy
- Vol. 15 (2), 101-107
- https://doi.org/10.1038/sj.cgt.7701101
Abstract
Anaplastic thyroid carcinoma is the most aggressive type of thyroid malignancies. Previously, we demonstrated that tumorigenicity of anaplastic thyroid carcinoma cell line ARO was significantly reduced following interleukin (IL)-12 gene transfer. We suspected that tumor target structure in ARO/IL-12 cells might be changed and such a change may make them more susceptible to be killed through mechanisms apart from natural killer-dependent pathway. To identify genes involved, we examined gene expression profile of ARO and ARO/IL-12 by microarray analysis of 3757 genes. The most highly expressed gene was cannabinoid receptor 2 (CB2), which was expressed eightfold higher in ARO/IL-12 cells than ARO cells. CB2 agonist JWH133 and mixed CB1/CB2 agonist WIN-55,212–2 could induce significantly higher rate of apoptosis in ARO/IL-12 than ARO cells. Similar results were obtained when ARO cells were transfected with CB2 transgene (ARO/CB2). A considerable regression of thyroid tumors generated by inoculation of ARO/CB2 cells was observed in nude mice following local administration of JWH133. We also demonstrated significant increase in the induction of apoptosis in ARO/IL12 and ARO/CB2 cells following incubation with 15 nM paclitaxel, indicating that tumor cells were sensitized to chemotherapy. These data suggest that CB2 overexpression may contribute to the regression of human anaplastic thyroid tumor in nude mice following IL-12 gene transfer. Given that cannabinoids have shown antitumor effects in many types of cancer models, CB2 may be a viable therapeutic target for the treatment of anaplastic thyroid carcinoma.Keywords
This publication has 28 references indexed in Scilit:
- Ribonucleic Acid Interference Targeting S100A4 (Mts1) Suppresses Tumor Growth and Metastasis of Anaplastic Thyroid Carcinoma in a Mouse ModelJournal of Clinical Endocrinology & Metabolism, 2006
- Anaplastic Thyroid Carcinoma: Biology, Pathogenesis, Prognostic Factors, and Treatment ApproachesAnnals of Surgical Oncology, 2006
- Gene Therapy of Cancer Based on Interleukin 12Current Gene Therapy, 2005
- Microarray Analysis of Metastasis-Associated Gene Expression Profiling in a Murine Model of Thyroid Carcinoma Pulmonary Metastasis: Identification of S100A4 (Mts1) Gene Overexpression as a Poor Prognostic Marker for Thyroid CarcinomaJournal of Clinical Endocrinology & Metabolism, 2004
- Human cancer gene therapy with cytokine gene-modified cellsExpert Opinion on Biological Therapy, 2004
- Gene therapy for thyroid cancerExpert Opinion on Biological Therapy, 2004
- Gene Therapy of Anaplastic Thyroid Carcinoma with a Single-Chain Interleukin-12 Fusion ProteinHuman Gene Therapy, 2003
- Cytokine gene therapy: Hopes and pitfallsAnnals Of Oncology, 1999
- A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995Cancer, 1998
- Molecular Basis of Thyroid Cancer*Endocrine Reviews, 1994